FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

Drug Reproductive Toxicity Testing Guide

Federal Register notice: FDA makes available a final guidance entitled S5(R3) Detection of Reproductive and Developmental Toxicity for Human Pharmaceu...

Medical Devices

Medtronic HeartWare HVAD System Recall is Class 1

FDA says the Medtronic recall of its HeartWare HVAD system to update instructions for use and the patient manual due to three issues is Class 1.

Medical Devices

J&J Vision PMA OKd for Myopia Contacts

FDA approves a Johnson & Johnson Vision PMA for its Acuvue Abiliti Overnight Therapeutic Lenses, the first orthokeratology contact lens for managing m...

Medical Devices

Desktop Health 3D Denture Material Cleared

FDA clears a Desktop Health 510(k) for its Flexcera Base, a proprietary resin for use in 3D fabrication of dental prosthetics.

Federal Register

Drug Guide on Q12 Technical and Regulatory Considerations

Federal Register notice: FDA makes available a final guidance entitled Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycl...

Human Drugs

Biopharmaceutics Classification Biowaivers Guidance

FDA publishes an International Council for Harmonization guidance on the Biopharmaceutics Classification System-based biowaivers.

Federal Register

FDA Withdrawing 12 No-Longer Marketed ANDAs

Federal Register notice: FDA withdraws approval of 12 ANDAs from multiple applicants after they notified the agency in writing that the drug products ...

Federal Register

Qualified Infectious Disease Product Designation Guide

Federal Register notice: FDA makes available a final guidance entitled Qualified Infectious Disease Product Designation Questions and Answers.

Federal Register

Guide on Developing Covid Drugs/Biologics

Federal Register notice: FDA makes available a final guidance entitled Covid-19: Developing Drugs and Biological Products for Treatment or Prevention....

Human Drugs

Rocket Pauses Phase 1 Danon Disease Trial

Rocket Pharmaceuticals says FDA asked it to pause patient dosing and modify the protocol for its Phase 1 trial of RP-A501 to treat Danon Disease.